Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, reported financial results for its fiscal first quarter ended September 30, 2009. Related posts Medical Health Insurance in Florida: Allegiance Financial Notes Many Finding Better Coverage by Leaving Their Employer Plans Behind (0) China Pharmaceuticals, [...]

Continue reading " Cardiovascular Systems Reports Fiscal First-Quarter 2010 Financial Results "

Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII) will host a live webcast of its fiscal 2010 first-quarter conference call on Wednesday, November 4, 2009, at 3:45 p.m. CT (4:45 p.m. ET). David L. Martin, president and chief executive officer, and Laurence L. Betterley, chief financial officer, will discuss the company’s results for the fiscal first quarter ended [...]

Continue reading " Cardiovascular Systems to Webcast Fiscal 2010 First-Quarter Earnings Conference Call Wednesday, November 4 "

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. Related posts Medical Health Insurance in Florida: Allegiance Financial Notes Many Finding Better Coverage by Leaving Their Employer Plans Behind [...]

Continue reading " Cardiovascular Systems Reports Fiscal Fourth-Quarter and Full-Fiscal 2009 Financial Results "

Cardiovascular Systems, Inc. (CSI)(Nasdaq: CSII) will host a live webcast of its fiscal fourth-quarter and full-year conference call on Wednesday, August 19, 2009, at 4 p.m. CT (5 p.m. ET). David L. Martin, president and chief executive officer of CSI, and Laurence L. Betterley, chief financial officer, will discuss the company’s results for the fiscal [...]

Continue reading " Cardiovascular Systems to Webcast Fiscal Fourth-Quarter and Full-Year 2009 Earnings Conference Call Wednesday, August 19 "

Oscient Pharmaceuticals Corporation (NASDAQ: OSCI) announced that it will discontinue sales force promotion of its two products: ANTARA (fenofibrate) capsules, a cardiovascular product and FACTIVE (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. Related posts Cardiovascular Systems Reports Fiscal First-Quarter 2010 Financial Results (0) Cardiovascular Systems to Webcast Fiscal 2010 First-Quarter Earnings Conference Call Wednesday, November 4 [...]

Continue reading " Oscient Pharmaceuticals Discontinues Sales Force Promotion for ANTARA and FACTIVE "